Navigation Links
Orexigen(R) Therapeutics to Present at Upcoming Investor Conferences
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of central nervous system disorders, including obesity, today announced that the Company will be presenting at the following upcoming investor conferences:

BioCentury Newsmakers in the Biotech Industry

Thursday, September 4, 2008, 10:00 AM Eastern time

Millennium Broadway Hotel, New York

UBS Global Life Sciences Conference

Tuesday, September 23, 2008, 9:30 AM Eastern time

Grand Hyatt Hotel, New York

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Orexigen(R) Therapeutics Schedules Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2008
2. OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
3. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
4. Nile Therapeutics to Present at BioCenturys NewsMakers in the Biotech Industry Conference
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. Cell Therapeutics, Inc. Announces Reverse Stock Split
7. Pixel Bridge Works With Anika Therapeutics to Launch New Website
8. Duska Therapeutics to Present at Noble Financial Equity M.A.D. MAX Conference on Tuesday, August 19th at 1:30 p.m. PDT
9. Arno Therapeutics Announces Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013 Edison ... firm, announces the initiation of full coverage ... company developing and marketing products for orphan ...      (Logo: http://photos.prnewswire.com/prnh/20130417/608168) Edison ... the investment merits of BioAlliance Pharma, focusing ...
(Date:6/18/2013)...  Techne Corporation (NASDAQ: TECH ) ... acquire 100% ownership of Bionostics Holdings Limited and ... a global leader in the development, manufacture and ... operation of in vitro diagnostic (IVD) ... glucose and blood gas testing.  Biosnostics has strategic ...
(Date:6/18/2013)... Texas , June 18, 2013   ... ), a biopharmaceutical company focused on discovering breakthrough ... John Northcott has joined the company as ... operations. Mr. Northcott brings extensive commercial experience to ... across a variety of therapeutic areas. ...
(Date:6/18/2013)... Inflamax Research Inc., a full ... Phase I-IV clinical trials, announced today that they ... Environmental Technologies (NAET), a specialty air conditioning & ... servicing of mobile Environmental Exposure Chambers (EECs) used ... , Inflamax Research has proprietary Next ...
Breaking Biology Technology:Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 2Edison Expands French Healthcare Sector Coverage With Initiation of Coverage on BioAlliance Pharma 3Techne Corporation Announces Acquisition Agreement 2Techne Corporation Announces Acquisition Agreement 3Techne Corporation Announces Acquisition Agreement 4Techne Corporation Announces Acquisition Agreement 5John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... the American Cancer Society, one in three people will ... lifetime. In an effort to improve patient care and ... has developed innovative medical imaging technologies that are allowing ... disease. , ,The latest cancer-fighting advancements from GE ...
... -- SoftSwitching Technologies' nationwide power-monitoring system is ... Outage Task Force in its newly released report ... that affected large portions of the Midwest and Northeast ... Federal Energy Regulatory Commission (FERC) and the Task Force ...
... Note: This is the first of a multi-part interview ... , managing director of the Wisconsin Alumni Research Foundation ... WARF initiative called Whats in it for Wisconsin Business. This ... foundation more accessible to companies throughout the state, as well ...
Cached Biology Technology:GE Medicals Technologies Aid Battle Against Cancer 2GE Medicals Technologies Aid Battle Against Cancer 3WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 2WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 3WTN Interviews: How WARF is Reaching Out to Businesses About Technology Developed in Wisconsin 4
(Date:6/18/2013)... in the Gulf of Mexico and a smaller than ... based on several NOAA-supported forecast models. , NOAA-supported modelers ... the Louisiana Universities Marine Consortium are forecasting that ... be between 7,286 and 8,561 square miles which could ... range from an area the size of Connecticut, Rhode ...
(Date:6/18/2013)... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ... in 2006. He performed his Ph.D. thesis research ...
(Date:6/18/2013)... 5% and 10% of breast and ovarian cancers are ... tumours are attributable to inherited mutations from the parents ... with these mutations, PARP inhibitors, which are currently in ... a new option for personalised cancer treatment, an alternative ... a fraction of these patients generate resistance to the ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4The American Society for Microbiology honors Joshua Obar 2An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
... response to an avian influenza vaccine with doses as ... a chemical mixture known as MF59. The research is ... Diseases, now available online. , MF 59 is ... to respond to a stimulus. For this research, the ...
... of endangered bird eggs made international headlines in May ... illegal egg collector, died after falling from a 12-meter ... Society for the Protection of Birds estimates that up ... by collectors. Classical economics theory predicts that such exploitation ...
... switch, the hepatitis C virus turns on human immune ... those defenses by manipulating interaction of key cellular proteins, ... This same molecular "on/off switch" controls immunity against many ... to fight viruses, the researchers report. , In ...
Cached Biology News:A human taste for rarity spells disaster for endangered species 2A human taste for rarity spells disaster for endangered species 3Molecular 'on/off switch' controls immune defenses against viruses 2
... Immunogen KLH-conjugated, synthetic ... 47-66 (PAEV-GPGAVGERTPRKKEPP) of human BRAF-HDAC ... (BHC110/LSD1). Quality Assurance ... Stability 2 years ...
Request Info...
...
...
Biology Products: